SCHEMBL4743327

SCHEMBL4743327

NC(=O)c1ccc(O)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
HSD17B10 Q99714 1/20 0.50
TTR P02766 1/20 0.48
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
ATM Q13315 1/20 0.47
BACE1 P56817 1/20 0.46
ESR1 P03372 1/20 0.45
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA7 P43166 3/20 0.45
CA9 Q16790 3/20 0.45
CA14 Q9ULX7 3/20 0.45
CES2 O00748 1/20 0.45
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA13 Q8N1Q1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7281430 0.84 MKNK2 (0.58) KMT2AMKNK1MKNK2ATMESR1
SCHEMBL201968 0.83 ALDH1A1 (0.51) KMT2AHSD17B10ATMESR1CA12
SCHEMBL31196555 0.83 ALDH1A1 (0.51) KMT2AHSD17B10ATMESR1CA12
SCHEMBL10369990 0.82 CES2 (0.60) HSD17B10TTRBACE1ESR1CA12
SCHEMBL1758840 0.82 HSD17B10 (0.54) KMT2AHSD17B10TTRBACE1ESR1
SCHEMBL13069724 0.80 HSD17B10 (0.52) HSD17B10TTRBACE1ESR1CA12
SCHEMBL945711 0.80 TSHR (0.65) KMT2AHSD17B10TTRESR1CA12
SCHEMBL29567497 0.80 TSHR (0.65) KMT2AHSD17B10TTRESR1CA12
SCHEMBL325007 0.80 SMN1; SMN2 (0.65) KMT2AMKNK1MKNK2ALDH1A1TSHR
SCHEMBL29506761 0.80 SMN1; SMN2 (0.65) KMT2AMKNK1MKNK2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117110458-A Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry 浙江工业大学 2023-11-24 CN claimed
EP-3056198-A2 USE OF COMPOUNDS FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO CHONDROCYTES MSP Co., Ltd (KR) 2016-08-17 EP claimed
EP-2617415-B1 USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION (KR) 2016-04-20 EP claimed
US-20150252003-A1 Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells MSP CO., LTD. (KR) 2015-09-10 US claimed
US-9068166-B2 Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) 2015-06-30 US claimed
US-20130236969-A1 Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2013-09-12 US claimed
EP-2617415-A2 USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS Industry-Academic Cooperation Foundation, Yonsei University (KR) 2013-07-24 EP claimed
CN-117110458-B Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry 浙江工业大学 2025-10-31 CN disclosed
CN-115515947-B SHP2 inhibitor, composition and application thereof 贝达药业股份有限公司 2024-02-06 CN disclosed
CN-117110458-A Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry 浙江工业大学 2023-11-24 CN disclosed
CN-117110458-A Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry 浙江工业大学 2023-11-24 CN disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 US disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 US disclosed
US-20150252003-A1 Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells MSP CO., LTD. (KR) 2015-09-10 US disclosed
US-9068166-B2 Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) 2015-06-30 US disclosed
US-20130236969-A1 Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2013-09-12 US disclosed
EP-2617415-A2 USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS Industry-Academic Cooperation Foundation, Yonsei University (KR) 2013-07-24 EP disclosed
WO-2008096093-A1 OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES ARGENTA DISCOVERY LTD. (GB) 2008-08-14 WO disclosed
WO-2008096093-A1 OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES ARGENTA DISCOVERY LTD. (GB) 2008-08-14 WO disclosed
US-6414013-B1 KINASE INHIBITORS; ANTICANCER AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130236969-A1 Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes COL2A1, MYADM, COL1A1 KMT2A 4177/4885HSD17B10 1381/4885TTR 4598/4885
US-20150252003-A1 Use of a Compound for Inducing Differentiation of Mesenchymal Stem Cells into Cartilage Cells COL2A1, MYADM, COL1A1 KMT2A 3942/4885HSD17B10 1344/4885TTR 4591/4885
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF PTPRF, PTPRCAP, PTPRJ KMT2A 3295/4885HSD17B10 2303/4885TTR 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.